Home Other Building Blocks 885012-33-9
885012-33-9,MFCD18633310
Catalog No.:AA01E5L1

885012-33-9 | Ar-9281

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
≥90%
in stock  
$46.00   $32.00
- +
5mg
≥90%
in stock  
$199.00   $139.00
- +
10mg
≥90%
in stock  
$348.00   $243.00
- +
50mg
≥90%
in stock  
$1,302.00   $911.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA01E5L1
Chemical Name:
Ar-9281
CAS Number:
885012-33-9
Molecular Formula:
C24H32N2O4
Molecular Weight:
412.5219
MDL Number:
MFCD18633310
SMILES:
O=C(N[C@]12CC3C[C@@H](C2)C[C@@H](C1)C3)N[C@@H]1CC[C@H](CC1)Oc1ccc(cc1)C(=O)O
Properties
Computed Properties
 
Complexity:
608  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
30  
Hydrogen Bond Acceptor Count:
4  
Hydrogen Bond Donor Count:
3  
Rotatable Bond Count:
5  
XLogP3:
4.6  

Literature

Title: Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.

Journal: American journal of physiology. Heart and circulatory physiology 20150501

Title: Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase inhibition in diabetic spontaneously hypertensive rats.

Journal: Clinical science (London, England : 1979) 20131001

Title: Adenosine A2A receptor modulates vascular response in soluble epoxide hydrolase-null mice through CYP-epoxygenases and PPARγ.

Journal: American journal of physiology. Regulatory, integrative and comparative physiology 20130101

Title: Effects of soluble epoxide hydrolase inhibitor on the expression of fatty acid synthase in peripheral blood mononuclear cell in patients with acute coronary syndrome.

Journal: Lipids in health and disease 20130101

Title: Chronic doxorubicin cardiotoxicity modulates cardiac cytochrome P450-mediated arachidonic acid metabolism in rats.

Journal: Drug metabolism and disposition: the biological fate of chemicals 20121101

Title: Soluble epoxide hydrolase gene deficiency or inhibition attenuates chronic active inflammatory bowel disease in IL-10(-/-) mice.

Journal: Digestive diseases and sciences 20121001

Title: t-AUCB, an improved sEH inhibitor, suppresses human glioblastoma cell growth by activating NF-κB-p65.

Journal: Journal of neuro-oncology 20120701

Title: Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension.

Journal: Clinical science (London, England : 1979) 20120601

Title: Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.

Journal: Bioorganic & medicinal chemistry 20120515

Title: Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats.

Journal: Experimental diabetes research 20120101

Title: Cytochrome P450-derived epoxyeicosatrienoic acids accelerate wound epithelialization and neovascularization in the hairless mouse ear wound model.

Journal: Langenbeck's archives of surgery 20111201

Title: Improved bioavailability of epoxyeicosatrienoic acids reduces TP-receptor agonist-induced tension in human bronchi.

Journal: American journal of physiology. Lung cellular and molecular physiology 20111101

Title: Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes.

Journal: American journal of physiology. Regulatory, integrative and comparative physiology 20111101

Title: Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles.

Journal: American journal of physiology. Renal physiology 20111001

Title: Increases in plasma trans-EETs and blood pressure reduction in spontaneously hypertensive rats.

Journal: American journal of physiology. Heart and circulatory physiology 20110601

Title: Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats.

Journal: American journal of physiology. Regulatory, integrative and comparative physiology 20110601

Title: Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase.

Journal: Journal of medicinal chemistry 20110428

Title: [The effects of soluble epoxide hydrolase inhibitors on cholesterol efflux in adipocytes].

Journal: Zhonghua nei ke za zhi 20110301

Title: [Effects of soluble epoxide hydrolase inhibitors on lipid metabolism and secretive functions of adipocytes].

Journal: Zhonghua yi xue za zhi 20110111

Title: Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension.

Journal: The Journal of physiology 20110101

Title: Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis.

Journal: The Journal of pharmacology and experimental therapeutics 20100801

Title: Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20100614

Title: Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model.

Journal: Biochemical pharmacology 20100315

Title: Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury.

Journal: Journal of cardiovascular pharmacology 20100101

Title: Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches.

Journal: Journal of molecular and cellular cardiology 20091201

Title: Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension.

Journal: American journal of physiology. Renal physiology 20090901

Title: Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection.

Journal: The American journal of pathology 20090601

Title: Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats.

Journal: Journal of hypertension 20090201

Title: Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation.

Journal: British journal of pharmacology 20090101

Title: Hydrolysis of cis- and trans-epoxyeicosatrienoic acids by rat red blood cells.

Journal: The Journal of pharmacology and experimental therapeutics 20080701

Title: Orally bioavailable potent soluble epoxide hydrolase inhibitors.

Journal: Journal of medicinal chemistry 20070809

Title: Microsphere-based protease assays and screening application for lethal factor and factor Xa.

Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 885012-33-9
Tags:885012-33-9 Molecular Formula|885012-33-9 MDL|885012-33-9 SMILES|885012-33-9 Ar-9281